COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT Russian patent published in 2023 - IPC A61K31/4427 A61K31/497 A61K31/506 A61K45/06 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to compositions and methods of treating cancer using SHP2 protein tyrosine phosphatase inhibitors as monotherapy and in combination with inhibitors of the RAS signaling pathway. A subject who has a cancer carrying certain RAS pathway oncogenic mutations is provided with an SHP2 inhibitor being a compound of formula I-V2.

Also a combination therapy agent and a pharmaceutical composition for the treatment of cancer associated with a mutation of the RAS pathway, containing an inhibitor of the RAS pathway and the specified SHP2 inhibitor is proposed. The RAS pathway mutation is selected from a KRAS mutation, a BRAF class 3 mutation, a MEK1 class I mutation, a MEK1 class II mutation, and an NF1 mutation. The RAS pathway inhibitor is either a MAPK inhibitor, a MEK inhibitor, or an ERK inhibitor.

EFFECT: effective suppression of growth or proliferation of a cell containing a RAS pathway mutation, as well as prevention and slowing down of resistance of tumors carrying RAS pathway mutations to RAS pathway inhibitors.

21 cl, 22 dwg, 5 tbl, 8 ex